CommercialCoverageHigh impact
Azacitidine (CPB 0960, reviewed 2026-06-12)
Aetna·Hematology, Oncology, Internal Medicine +1 more·Medical Policy
Effective date
Jun 12, 2026
We identified it
Aug 12, 2026
Summary
Aetna updated its Clinical Policy Bulletin for Azacitidine (CPB 0960) effective June 12, 2026, clarifying coverage criteria for multiple hematologic and oncologic malignancies. The policy specifies approved indications including MDS, AML, MDS/MPN overlap syndromes, and peripheral T-cell lymphoma (PTCL) as single-agent subsequent therapy for relapsed/refractory disease, along with dosing requirements and continuation criteria. Billing teams must ensure claims match these specific indications and document medical necessity for off-label uses, which remain experimental.
Action Required
By June 12, 2026: Billing team must update authorization and claim submission protocols for azacitidine (J9025). (1) Verify all azacitidine claims match one of the approved indications listed in policy criteria: MDS, AML, accelerated/blast phase MPN, BPDCN with venetoclax, MDS/MPN overlap syndromes (CMML, JMML, aCML, etc.), or PTCL as single-agent subsequent therapy for relapsed/refractory disease. (2) For PTCL claims, require documentation that medication is used as monotherapy (not combination) for relapsed or refractory disease; deny claims for frontline or combination PTCL therapy. (3) Verify chemotherapy administration codes (96401, 96413-96417) are paired with approved ICD-10 diagnosis codes only. (4) Flag any indication not on the approved list as experimental/investigational and prepare denial notices. (5) Update claim scrubbing rules in billing system to require prior authorization confirmation before payment. (6) Providers must document dose appropriateness (75-100 mg/m² for MDS, age/weight-based for pediatric JMML) and treatment duration (minimum 4-6 cycles for MDS, 3-6 cycles for JMML). Claims lacking this documentation or using off-label indications will be denied.